One pharmaceutical lobbyist told BioPharma Dive the Trump administration’s drug pricing blueprint lets the pharmaceutical industry take a deep breath; others say the plan will have little effect on the rising health care spending.
“There are no major surprises, it spares the pharmaceutical industry of the reform that they most vehemently oppose,” the unidentified lobbyist said after Trump’s speech. “Real reforms that advocates say will move the needle, none of them are included. There’s a lot of tinkering around the edges.”
Among the recommendations included in the blueprint, according to a BioPharma Dive report, the administration says it will work to address abuse of the Food and Drug Administration’s Risk Evaluation mitigation Strategy programs to help generic drugs more quickly hit the market.
The administration is also considering list prices in consumer drug advertising, Health and Human Services Secretary Alex Azar said after Trump’s speech.
“Think about all the time everybody spends watching drug company ads, and how much information companies are required to put in them,” Azar said. “If we want to have a real market for drugs, why not have them disclose their prices in the ads, too?”
To read the full report on Healthcare Dive, click here.